The government alleges Labcorp and UHS delayed submission of orders for tests by Caris Life Sciences to enable improper billings to Medicare for those tests.

NEW YORK – Anbio Biotechnology filed this week a preliminary prospectus for an initial public offering on the Nasdaq exchange of 1.6 million shares at an anticipated offering price in the range of $5 ...

NEW YORK – After two years of decline in 2022 and 2023, the 360Dx Top 30 rebounded in 2024, rising 4 percent year over year.

The agency made multiple decisions regarding coverage for diagnostic and laboratory testing that have affected the industry.

Only 20 full-company mergers or acquisitions occurred throughout the year, although asset acquisition deals were more common.

Firms in the space advanced solutions to stratify sepsis patients and accelerated time-to-results to find out the cause of infections.

The firm received notice that it had failed to regain compliance with the Nasdaq's requirement to maintain a minimum $35 million market value of listed securities.

In Brief This Week: Labcorp, Abbott, Danaher, MeMed, Co-Diagnostics, More ...

Editor’s Note: We will adjust the firms listed in the 360Dx Top 30 this month based on market caps at the end of 2024. Those changes will be reflected next month when we report on the stock ...